Clinical Trials

60 enrolled

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07472647 2026-03-16

SYS6090 Combination Therapy in Advanced Lung Cancer

596 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT07465757 2026-03-12

ALISCA-Lung2

Small Cell Lung Carcinoma

NCT07286331 2026-03-11

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

600 enrolled

Endometrial Neoplasms

NCT07463573 2026-03-11

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

466 enrolled

Esophageal Squamous Cell Carcinoma

NCT07441486 2026-03-02

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Breast Neoplasms

NCT07441681 2026-03-02

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

454 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07416474 2026-02-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

574 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07419295 2026-02-19

TroFuse-031

590 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT07418749 2026-02-18

A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer

398 enrolled

Uterine Cervical Neoplasms

NCT07418931 2026-02-18

CECYDE

108 enrolled

Phase 1 Not yet recruiting

Advanced Squamous Non-Small Cell Lung Cancer

NCT07300475 2026-02-13

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

30 enrolled

Triple Negative Breast Neoplasms

NCT07407452 2026-02-12

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

Ovarian Neoplasms

NCT07400094 2026-02-10

NeoCamre-HN

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Mouth Neoplasms

NCT07401654 2026-02-10

The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression

60 enrolled

Ovarian Neoplasms

NCT07396324 2026-02-09

NEO-ITHRAN

55 enrolled

Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

NCT07283692 2026-02-03

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

46 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05411237 2026-01-23

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

130 enrolled

Sarcoma

AIDS-related Kaposi sarcoma, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT07360132 2026-01-22

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

480 enrolled

Squamous Non-small Cell Lung Cancer

NCT07020065 2026-01-21

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

156 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07346196 2026-01-20

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

Phase 1 Not yet recruiting

90 enrolled

Tumor-Agnostic

Carcinoma, Squamous Cell

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

90 enrolled

BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

NCT07247786 2025-12-30

MIGRANT

68 enrolled

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

NCT07309952 2025-12-30

SACTION 2501

28 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07304258 2025-12-26

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

30 enrolled

Gastric Cancer Peritoneal Metastases

NCT07298772 2025-12-23

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

198 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06492759 2025-12-16

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

29 enrolled

Triple Negative Breast Neoplasms

NCT07286266 2025-12-16

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

450 enrolled

Ovarian Neoplasms

NCT07265739 2025-12-11

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

27 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT07274384 2025-12-10

HYPERBOLIC

74 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT06914011 2025-12-03

MRD2START

172 enrolled

Esophageal Neoplasms

NCT07262567 2025-12-03

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

320 enrolled

Phase NA Not yet recruiting

Pancreatic Neoplasms

NCT07187674 2025-09-23

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

20 enrolled

Triple Negative Breast Neoplasms

NCT07001618 2025-07-23

IMMUNOLIFE2

162 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07028424 2025-07-01

PANORAMIX

206 enrolled

PDAC - Pancreatic Ductal Adenocarcinoma

NCT07045805 2025-07-01

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

66 enrolled

Stomach Neoplasms

NCT06904300 2025-06-05

Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

110 enrolled

Tumor-Agnostic

Neoplasms

NCT06980545 2025-05-20

Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

Stage III and IV Ovarian Cancer

NCT06944470 2025-04-25

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

76 enrolled

NSCLC

NCT06870565 2025-03-17

Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma

238 enrolled

Uterine Cervical Neoplasms

NCT06867562 2025-03-10

Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer

166 enrolled

Platinum-Resistant Primary Peritoneal Carcinoma

NCT06751485 2024-12-31

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

430 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06751277 2024-12-27

QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

26 enrolled

Recurrence, Endometrial Neoplasms

NCT06745193 2024-12-20

A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer

63 enrolled

Advanced Esophageal Carcinoma

NCT06713057 2024-12-03

Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer

20 enrolled

Thyroid Neoplasms

NCT06699498 2024-11-21

Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

45 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

380 enrolled

Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06662669 2024-10-29

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

120 enrolled